Literature DB >> 8862609

Evaluation of an infectivity standard for real-time quality control of human immunodeficiency virus type 1 quantitative micrococulture assays. Participating Laboratories of The AIDS Clinical Trials Group.

W A Scott1, D Brambilla, E Siwak, C Beatty, J Bremer, R W Coombs, H Farzadegan, S A Fiscus, S M Hammer, F B Hollinger, N Khan, S Rasheed, P S Reichelderfer.   

Abstract

Quantitative microculture assays of cryopreserved human immunodeficiency virus type 1-infected cell suspensions and culture supernatants were compared among seven assays sites. There was no significant change in titer during 1 year of storage. The overall standard deviation for infected cell suspensions was approximately 0.8 log10 virus titer. A method for detecting deviant assay results was developed and was used to identify two donor cell preparations (n = 54) that gave consistently low titers.

Entities:  

Mesh：

Year:  1996        PMID： 8862609      PMCID： PMC229242          DOI： 10.1128/jcm.34.9.2312-2315.1996

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


  29 in total

1.  Susceptibility of normal human lymphocytes to infection with HTLV-III/LAV.

Authors:  T Folks; J Kelly; S Benn; A Kinter; J Justement; J Gold; R Redfield; K W Sell; A S Fauci
Journal:  J Immunol       Date:  1986-06-01       Impact factor: 5.422

2.  Neutralization of primary HIV-1 isolates by anti-envelope monoclonal antibodies.

Authors:  M P D'Souza; G Milman; J A Bradac; D McPhee; C V Hanson; R M Hendry
Journal:  AIDS       Date:  1995-08       Impact factor: 4.177

Review 3.  AIDS pathogenesis: a finite immune response to blame?

Authors:  F Miedema; M R Klein
Journal:  Science       Date:  1996-04-26       Impact factor: 47.728

4.  Human immunodeficiency virus type 1 quantitative cell microculture as a measure of antiviral efficacy in a multicenter clinical trial.

Authors:  S A Fiscus; V DeGruttola; P Gupta; D A Katzenstein; W A Meyer; M L LoFaro; M Katzman; M V Ragni; P S Reichelderfer; R W Coombs
Journal:  J Infect Dis       Date:  1995-02       Impact factor: 5.226

5.  Optimization of quantitative culture assay for human immunodeficiency virus from plasma. Plasma Viremia Group Laboratories of the AIDS Clinical Trials Group (National Institute of Allergy and Infectious Diseases).

Authors:  J L Lathey; S A Fiscus; S Rasheed; J C Kappes; B P Griffith; T Elbeik; S A Spector; P S Reichelderfer
Journal:  J Clin Microbiol       Date:  1994-12       Impact factor: 5.948

6.  Random-effects models for longitudinal data.

Authors:  N M Laird; J H Ware
Journal:  Biometrics       Date:  1982-12       Impact factor: 2.571

7.  Standardization of sensitive human immunodeficiency virus coculture procedures and establishment of a multicenter quality assurance program for the AIDS Clinical Trials Group. The NIH/NIAID/DAIDS/ACTG Virology Laboratories.

Authors:  F B Hollinger; J W Bremer; L E Myers; J W Gold; L McQuay
Journal:  J Clin Microbiol       Date:  1992-07       Impact factor: 5.948

8.  Detection of plasma viremia in human immunodeficiency virus-infected individuals at all clinical stages.

Authors:  L Z Pan; A Werner; J A Levy
Journal:  J Clin Microbiol       Date:  1993-02       Impact factor: 5.948

9.  Sensitive microculture method for isolation of human immunodeficiency virus type 1 from blood leukocytes.

Authors:  A Erice; K J Sannerud; V L Leske; D Aeppli; H H Balfour
Journal:  J Clin Microbiol       Date:  1992-02       Impact factor: 5.948

10.  Cell-free plasma human immunodeficiency virus type 1 titer assessed by culture and immunocapture-reverse transcription-polymerase chain reaction.

Authors:  R W Coombs; D R Henrard; W F Mehaffey; J Gibson; E Eggert; T C Quinn; J Phillips
Journal:  J Clin Microbiol       Date:  1993-08       Impact factor: 5.948
View more
  1 in total

1.  Neutralization profiles of sera from human immunodeficiency virus (HIV)-infected individuals: relationship to HIV viral load and CD4 cell count.

Authors:  M Nokta; P Turk; K Loesch; R B Pollard
Journal:  Clin Diagn Lab Immunol       Date:  2000-05
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.